# A Study to Assess the Pharmacokinetics of CC-90001 in Subjects With Mild, Moderate, and Severe Hepatic Impairment Compared With Healthy Subjects

> **NCT03742882** · PHASE1 · COMPLETED · sponsor: **Celgene** · enrollment: 40 (actual)

## Conditions studied

- Hepatic Impairment

## Interventions

- **DRUG:** CC-90001

## Key facts

- **NCT ID:** NCT03742882
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-06
- **Primary completion:** 2019-06-10
- **Final completion:** 2019-06-10
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2020-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03742882

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03742882, "A Study to Assess the Pharmacokinetics of CC-90001 in Subjects With Mild, Moderate, and Severe Hepatic Impairment Compared With Healthy Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03742882. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*